Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LGND

LGND - Ligand Pharmaceuticals Inc Stock Price, Fair Value and News

$190.25-5.24 (-2.68%)
Market Closed

28/100

LGND

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

28/100

LGND

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$160.92

Target 3M

$181.04

Target 6M

$170.98

LGND Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LGND Price Action

Last 7 days

-4.6%

Last 30 days

-2.5%

Last 90 days

1.7%

Trailing 12 Months

61.1%

LGND RSI Chart

LGND Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LGND Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

77.08

Price/Sales (Trailing)

14.9

EV/EBITDA

36.99

Price/Free Cashflow

121.73

LGND Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$160.92

Target 3M

$181.04

Target 6M

$170.98

LGND Fundamentals

LGND Revenue

Revenue (TTM)

251.2M

Rev. Growth (Yr)

122.85%

Rev. Growth (Qtr)

142.43%

LGND Earnings

Earnings (TTM)

48.6M

Earnings Growth (Yr)

1.7K%

Earnings Growth (Qtr)

2.3K%

LGND Profitability

EBT Margin

25.07%

Return on Equity

5.11%

Return on Assets

3.29%

Free Cashflow Yield

0.82%

LGND Investor Care

Shares Dilution (1Y)

4.16%

Diluted EPS (TTM)

2.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025181.5M187.6M251.2M0
2024118.3M133.5M152.4M167.1M
2023203.7M179.9M153.6M131.3M
2022231.5M202.7M202.3M196.2M
2021199.8M237.3M255.1M241.5M
2020110.0M126.4M143.4M186.4M
2019238.8M173.7M152.9M120.3M
2018251.5M251.5M251.5M251.5M
2017135.5M206.0M230.0M251.5M
201687.0M88.1M92.0M109.0M
201563.2M71.0M73.7M71.9M
201453.3M54.3M56.3M64.5M
201337.4M41.2M47.9M49.0M
201231.8M30.1M30.7M31.4M
201121.5M23.1M21.0M30.0M
201000023.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Ligand Pharmaceuticals Inc

LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
 CEO
 WEBSITEligand.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES76

Ligand Pharmaceuticals Inc Frequently Asked Questions

LGND is the stock ticker symbol of Ligand Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ligand Pharmaceuticals Inc is 3.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LGND's fair value in chart for subscribers.

The fair value guage provides a quick view whether LGND is over valued or under valued. Whether Ligand Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ligand Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LGND.

As of Wed Jan 28 2026, LGND's PE ratio (Price to Earnings) is 77.08 and Price to Sales (PS) ratio is 14.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LGND PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ligand Pharmaceuticals Inc has provided 0.118 (multiply by 100 for percentage) rate of return.